Dopamine agonist
Stimulates dopamine D2/D3 receptors, improving dopaminergic transmission in basal ganglia and limbic circuits
Parkinson’s disease (PD), moderate-to-severe primary restless legs syndrome (RLS)
Depression in PD, post-stroke apathy, treatment-resistant depression augmentation
Oral immediate-release and extended-release tablets
0.125 mg p.o. daily, titrate by 0.125 mg every 5–7 days
0.125–1.5 mg/day
Renal excretion; half-life ~8–12 hours
Nausea, orthostatic hypotension, somnolence, edema
Impulse-control disorders, hallucinations
Monitor renal function, psychiatric status, impulse-control symptoms
None
Increased risk of confusion and hallucinations in dementia; caution in elderly; monitor carefully in patients with cognitive impairment.